There is some new medical research about current population-based estimates of the incidence of breast implants-associated anaplastic large cell lymphoma (BIA-ALCL) — more commonly called breast implants lymphoma cancer — in the US, and the findings are rather alarming.
From this recent news report, “ALCL Increasing Rapidly in US Women as Breast Implants Rise“, about that recent medical journal article:
The team, led by Connor Kinslow, MD, Columbia University, New York City, looked at the age-adjusted annual incidence rate of ALCL and found that it increased over time.
The incidence was 3.2 per 100 million persons per year from 2000-2005, then increased to 4.4 per 100 million persons per year from 2006-2011, and then tripled to an incidence of 14.5 per 100 million persons per year from 2012-2018….
These current incidence estimates are much higher than the previous estimate of 3 per 100 million persons per year quoted by the Food and Drug Administration (FDA), which had been based on data from the Surveillance, Epidemiology and End Results (SEER) data base from 2001-2007, the authors note.
“These trends are concerning, as the use of textured implants increased more than 5-fold from 2.3% to 13% of augmentation procedures between 2011 and 2015, despite a safety communication from the FDA in 2011,” they comment.
Our law firm has been representing several women diagnosed with breast implants lymphoma cancer. As such, we are monitoring the BIA-ALCL medical situation and will present add significant developments going forward on the Breast Implants Lymphoma Cancer page on our law firm website, where we offer a free case evaluation if you or someone you know has been diagnosed with BIA-ALCL.[Read article in full at original source]